breast cancer nefopam, breast cancer, postoperative pain, breast surgery
Conditions
Interventions
nefopam 20 mg diluted in 100 ml of normal saline, administered intravenously after induction of general anesthesia, then nefopam 60 mg diluted in 500 ml of normal saline, administered intravenously in
Active Comparator Drug,Placebo Comparator No treatment
nefopam ,Normal saline
Sponsors
Rajavithi Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with breast cancer and scheduled for elective total mastectomy with lymph node dissection 2. ASA physical status 1-3 3. Undergoing general anesthesia with endotracheal intubation 4. Able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding 2. Allergy to nefopam, morphine, or ibuprofen 3. Contraindication to use nefopam such as history of seizure disorder, epilepsy, angle-closure glaucoma, ischemic heart disease, severe hepatic(Child-Turcott-Pugh more than class) and chronic kidney disease stage 3 and above 4. Previous breast surgery on the same side 5. Unable to understand and use patient-controlled analgesia (PCA)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain score at 6,12 and 24 hours after intervention numerical rating score | — |
Secondary
| Measure | Time frame |
|---|---|
| Total morphine consumption 24 hours miligrams | — |
Countries
Thailand
Contacts
Public Contactsuttada ammaraporn
Rajavithi Hospital
Outcome results
None listed